<DOC>
	<DOCNO>NCT02358694</DOCNO>
	<brief_summary>This study conduct see serum-derived bovine immunoglobulin/protein isolate ( SBI ) safe well tolerate pediatric patient IBS-D. Main Hypothesis : Pediatric patient IBS-D , take SBI , significant adverse event 4 8 week quality life well patient receive placebo .</brief_summary>
	<brief_title>Safety Tolerability Serum Derived Bovine Immunoglobulin Children With Diarrhea Predominant IBS</brief_title>
	<detailed_description>The study consist four phase : Screening Phase : screen patient 2 week prior enrollment study establish objective criterion disease presence severity . Patients maintain daily symptom dairy . At end screen phase , calculate quality life symptom severity score base information provide patient family . Patients average score 1 great 14 day abdominal pain stool consistency select open label trial SBI . Open Label Treatment Phase : patient enrol receive 4 week SBI along QOL questionnaires complete . If patient 's global assessment improve , review diary show improvement symptom severity score ( decrease symptom severity score &gt; 30 % baseline ) , eligible randomization phase . Patients , improvement first 4 week SBI therapy , randomize . If non-responders worsen symptom , prescribe rescue medication per standard care . If non-responders choose continue take SBI , allow . Randomization Phase : Patients qualify phase randomize either SBI placebo . They take medication 4 week complete questionnaire , symptom well QOL . After 4 week phase patient offer Open Label Extension Phase . Open Label Extension Phase : All patient enter phase treat SBI another 16 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male female patient &gt; 8 year age &lt; 18 year age Patients diagnosis IBSD per Rome III criterion Patients normal laboratory work ( CBC , ESR , CRP , amylase , lipase , celiac panel , fecal occult blood ) Patients normal fecal calprotectin lactose hydrogen breath test Patients motility drug , NSAIDs least 2 week prior enrollment study Ability complete study Patients stable dos medication least 4 week prior enrollment Patients h/o GI , hepatic , renal , cardiovascular , neurologic hematological disorder Patients family history inflammatory bowel disease Patients history abdominal surgery Patient history drug alcohol abuse Patient history allergy study relate product ( e.g . beef ) Use probiotic previous month Patients use SBI past Patients soy allergy/sensitivity</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>IBS</keyword>
	<keyword>IBS-D</keyword>
	<keyword>SBI</keyword>
</DOC>